

C25

# Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER

Wei Liao,\* To Y. Hui,\* Stephen G. Young,<sup>†</sup> and Roger A. Davis<sup>1,\*</sup>

Mammalian Cell and Molecular Biology Laboratory,\* San Diego State University, San Diego, CA 92182-4614; and Gladstone Institute of Cardiovascular Disease,<sup>†</sup> Cardiovascular Research Institute, and Department of Medicine, University of California, San Francisco, CA 94110

**Abstract** Microsomal triglyceride transfer protein (MTP) is an intraluminal protein in the endoplasmic reticulum (ER) that is essential for the assembly of apolipoprotein B (apoB)-containing lipoproteins. In this study, we examine how the livers of mice respond to two distinct methods of blocking MTP function: Cre-mediated disruption of the gene for MTP and chemical inhibition of MTP activity. Blocking MTP significantly reduced plasma levels of triglycerides, cholesterol, and apoB-containing lipoproteins in both wild-type C57BL/6 and LDL receptor-deficient mice. While treating LDL receptor-deficient mice with an MTP inhibitor for 7 days lowered plasma lipids to control levels, liver triglyceride levels were increased by only 4-fold. Plasma levels of apoB-100 and apoB-48 fell by >90% and 65%, respectively, but neither apoB isoform accumulated in hepatic microsomes. Surprisingly, loss of MTP expression was associated with a nearly complete absence of apoB-100 in hepatic microsomes. Levels of microsomal luminal chaperone proteins [e.g., protein disulfide isomerase, glucose-regulated protein 78 (GRP78), and GRP94] and cytosolic heat shock proteins (HSPs) (e.g., HSP60, HSC, HSP70, and HSP90) were unaffected by MTP inhibition. These findings show that the liver responds rapidly to inhibition of MTP by degrading apoB and preventing its accumulation in the ER. The rapid degradation of secretion-incompetent apoB in the ER may block the induction of proteins associated with unfolded protein and heat shock responses.—Liao, W., T. Y. Hui, S. G. Young, and R. Davis. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. *J. Lipid Res.* 2003. 44: 978–985.

**Supplementary key words** apolipoprotein B • endoplasmic reticulum • hyperlipidemia • liver • inflammation • unfolded protein response

VLDLs produced by the liver are the major source of LDLs in the plasma, which are causally related to the de-

velopment of atherosclerotic cardiovascular disease (1). The importance of the hepatic secretion of apolipoprotein B (apoB) in cardiovascular disease was recognized in early studies of abetalipoproteinemic patients, who lack the ability to secrete apoB-containing lipoproteins (2) and are markedly resistant to cardiovascular disease (3). Subsequent studies showed that specific mutations in the microsomal triglyceride transfer protein (MTP) gene are responsible for abetalipoproteinemia (4, 5). MTP exists in a functional complex with protein disulfide isomerase (PDI) (6, 7). The loss of MTP function blocks the secretion of apoB-containing lipoproteins from both the liver and the intestine (5). Apart from neuropathy, which can be prevented by vitamin E supplements (8) and moderate steatosis in enterocytes and hepatocytes, abetalipoproteinemia is not usually associated with liver failure or cirrhosis (3). The absence of severe symptoms has suggested that inactivation of MTP might be a useful strategy for combating hyperlipidemia and cardiovascular disease.

Several chemical inhibitors of the lipid transfer activity of MTP have been developed (9–12). Many of these inhibitors lower plasma lipid levels in animal models (11–13). Especially encouraging results were obtained in Watanabe-heritable hyperlipidemic rabbits, a model of homozygous familial hypercholesterolemia (13). Administration of an MTP inhibitor to Watanabe-heritable hyperlipidemic rabbits reduced plasma lipid and lipoprotein levels to normal (13). Since many homozygous familial hypercholesterolemias are resistant to statin therapies (14), MTP inhibitors might provide a more attractive treatment to liver transplantation, which effectively reduces atherosclerosis in these patients (15).

Abbreviations: ALLN, acetylated leucine, leucine, norleucine; ER, endoplasmic reticulum; GRP, glucose-regulated protein; HSP, heat shock protein; MTP, microsomal triglyceride transfer protein; PDI, protein disulfide isomerase.

<sup>1</sup> To whom correspondence should be addressed.  
e-mail: rdavis@sunstroke.sdsu.edu

Manuscript received 14 January 2003 and in revised form 14 February 2003.  
Published, JLR Papers in Press, February 16, 2003.  
DOI 10.1194/jlr.M300020-JLR200

Copyright © 2003 by Lipid Research, Inc.

Downloaded from www.jlr.org by on July 31, 2007



MTP inhibitor drugs have provided the opportunity to examine the processes regulating the assembly, secretion, and degradation of apoB-containing lipoproteins. Studies of cultured cells suggest that the cotranslational translocation of apoB into the lumen of the endoplasmic reticulum (ER) governs the fate of newly synthesized apoB [reviewed in refs. (16–20)]. Unlike other proteins secreted by the liver, apoB-100 cannot be completely translocated into the ER lumen without MTP (21–23). MTP appears to facilitate both the folding and lipidation of apoB during translocation (24–32). In the absence of MTP, apoB translocation is abrogated, resulting in the rapid cotranslational degradation of the cytoplasmic, translocation-arrested C terminus of apoB (33) via the proteasome (34–36). Approximately 85 kDa of the N-terminal portion of translocation-arrested apoB is released from the ER membrane, enters the lumen, and can be secreted or degraded (21, 24, 37). The finding that plasma from abetalipoproteinemic patients was enriched with an 85 kDa N-terminal peptide compared with plasma from unaffected family members suggested that MTP-facilitated translocation occurs in the human liver (24). Several additional degradative processes act to ensure that secretion-incompetent apoB does not accumulate [reviewed in refs. (16–20)]. Preventing the accumulation of apoB within the secretory pathway may be essential in preventing an induction of unfolded-protein response (38–40).

To our knowledge, there have been no published studies that have examined how the liver in vivo responds to loss of MTP in regard to the accumulation of apoB and possible induction of unfolded protein and/or heat shock responses. Our studies revealed that the inactivation of MTP (by gene disruption or chemical inactivation) led to a block in the secretion of apoB and prevented its accumulation in the ER, as well as the induction of unfolded protein and/or heat shock responses.

## EXPERIMENTAL PROCEDURES

### Materials

The MTP inhibitor 8aR (11) was kindly provided by Dr. Gary Ksander (Novartis, Summit, NJ). Antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Mice homozygous for both a conditional *Mtp* allele (*Mtp<sup>lox</sup>*) and the *Mx1-Cre* transgene have been described (22). Wild-type C57BL/6 mice and C57BL/6 LDL receptor knockout mice (*Ldlr<sup>-/-</sup>*) were obtained from The Jackson Laboratory (<http://www.jax.org>).

### Animal procedures

Mice were maintained under standard conditions on a 12 h light-dark cycle (lights on from 0600 to 1800). To eliminate MTP expression in the liver, 8-week-old *Mtp<sup>lox/lox</sup>Mx1-Cre<sup>+/+</sup>* mice were injected with polyinosinic-polycytidylic ribonucleic acid (polyIC; Sigma; 300 µg every two days for 5 times). Control mice received vehicle only. Three or six weeks after last injection, blood was drawn from the retro-orbital plexus into tubes containing EDTA, and plasma was separated by centrifugation. The mice were killed by cervical dislocation, and the livers were removed immediately and used to prepare microsomes (33). All

protocols were approved by the Animal Care and Use Committee of San Diego State University.

### MTP inhibitor experiments

The inhibitor 8aR was prepared as a water suspension in 3% cornstarch, and was administered orally at a dose of 50 mg/kg daily for 7 days, or using as a single dose of 100 mg/kg.

### Preparation of microsomes

The liver was homogenized in 250 mM sucrose and 10 mM Hepes (pH 7.4) containing 1 mM phosphomethylsulfonyl fluoride, 0.1 mM acetylated leucine, leucine-norleucal (ALLN), and 5 mM *N*-ethylmaleimide. Microsomes were obtained by ultracentrifugation and washing of fractions, as described (33). The protein concentration in the samples was measured using a protein assay kit (Bio-Rad, Hercules, CA).

### Immunoblot analysis

Equal amounts of proteins from liver homogenates, microsomes, or plasma were separated by SDS-PAGE, transferred to nitrocellulose membranes, and probed with primary antibodies as described (21). Blots were detected by enhanced chemiluminescence (ECL kit, Amersham). The relative intensity of the immunoblot bands was quantified with a Storm PhosphorImager, (Amersham Pharmacia Biotech, Piscataway, NJ).

### Size fractionation of lipoproteins by fast protein liquid chromatography

Equal volumes of plasma from each mouse in each group were pooled (0.2 ml) and loaded onto a fast protein liquid chromatography (FPLC) system with two Superose 6B columns connected in series (HR10/30, Pharmacia FPLC System, Amersham Pharmacia Biotech) (41). Fractions (1 ml) were collected at a flow rate of 0.5 ml/min with an elution buffer (15 mM NaCl, 0.01% EDTA, 0.02% sodium azide, pH 7.3).

### Cholesterol and triglyceride assays

Cholesterol and triglycerides in plasma and FPLC fractions were assayed with commercial kits from Sigma, as described (41).


### Statistical analysis

Results are given as the mean  $\pm$  SD. Statistical significance was determined by Student's *t*-test with two-tailed *P* values. Differences were considered to be significant at *P* < 0.05.

## RESULTS

### Effects of disrupting *Mtp* in the liver

For our studies, we used *Mtp<sup>lox/lox</sup>Mx1-Cre<sup>+/+</sup>* mice. *Cre* expression in these mice can be induced with polyIC, which eliminates exon 1 of *Mtp* and prevents the formation of a functional *Mtp* transcript (22). The absence of MTP expression by the liver did not affect body weight, but increased liver weight (Fig. 1A) and reduced the plasma levels of triglycerides (45%) and cholesterol (60%) (Fig. 1B). As a result, VLDL, IDLs, and LDLs were almost undetectable, and HDL levels were reduced by ~50% (Fig. 1B). Hepatic triglycerides were increased 2.5-fold, and hepatic cholesterol was increased by 65% (Fig. 1C). ApoB-100 was reduced to undetectable levels in plasma, and plasma levels of apoB-48 were reduced by ~65% (Fig. 1D). Surprisingly, loss of MTP expression was




**Fig. 1.** Effect of liver-specific deletion of microsomal triglyceride transfer protein (MTP) on the plasma and liver levels of apolipoprotein B (apoB)-containing lipoproteins. Female *Mtp<sup>fllox/fllox</sup>Mx1-Cre<sup>+/+</sup>* mice (8 weeks old) were injected with polyIC ip (300 µg every other day, five times) or saline only (control). Three weeks after the last injection, mice were sacrificed and plasma and liver were obtained and analyzed. **A:** Body and liver weights. **B:** Plasma triglyceride and cholesterol, and cholesterol in each fraction obtained from FPLC separation of pooled plasma (n = 5/group). **C:** Liver triglyceride and cholesterol. **D:** Immunoblot analysis of plasma detected with an anti-apoB antibody. **E:** Immunoblot analysis of liver microsomes detected with an anti-apoB antibody. **F:** Immunoblot analysis of liver microsomes detected with antibodies as indicated. Each bar graph value represents the mean ± SD. \*P < 0.02.

associated with a nearly complete absence of apoB-100 in hepatic microsomes. The amount of apoB-48 was unaffected (Fig. 1E). The lack of MTP expression did not affect the levels of microsomal luminal chaperone proteins (e.g., PDI, glucose-regulated protein (GRP) 78 and GRP94) or cytosolic heat shock proteins (HSPs) (e.g., HSP60, HSC, HSP70, and HSP90) (Fig. 1F). Hepatic microsomes from mice treated for 6 weeks with polyIC contained no detectable MTP protein (Fig. 1F). Northern blots showed that apoB mRNA levels were unchanged by polyIC treatment (not shown). Thus, changes in apoB were the result of the absence of hepatic MTP expression. These data suggest that deletion of hepatic MTP expression blocks the assembly and secretion of apoB-containing lipoproteins without causing apoB-100 or apoB-48 to accu-

mulate in the ER. This experiment was repeated twice with similar results (not shown).

#### Consequences of blocking MTP with chemical inhibitors

We next examined how mice responded to chemical inhibition of MTP. After 7 days of treatment with 8aR, the phenotype of C57BL/6 mice was essentially the same as that of mice lacking hepatic MTP. The liver weight increased (Fig. 2A), the plasma levels of triglyceride (50%) and cholesterol (70%) decreased (Fig. 2B), and the liver content of triglyceride (4-fold) and cholesterol (35%) increased (Fig. 2C). The MTP inhibitor markedly decreased plasma levels of apoB-48 (70%) and apoB-100 (95%) (Fig. 2D). Hepatic microsomes from 8aR-treated mice contained almost no apoB-100, and there was no accumula-



**Fig. 2.** Effect of 7 days of treatment with an oral MTP inhibitor on the plasma and liver levels of apoB-containing lipoproteins in C57BL/6 mice. Female C57BL/6 mice (8 weeks old) were given the MTP inhibitor 8aR (50 mg/day/kg) for 7 days at 0800 h or vehicle only (control). Mice were sacrificed at 1100 h, and plasma and livers were obtained and analyzed. **A:** Body and liver weights. **B:** Plasma triglyceride and cholesterol levels. **C:** Liver triglyceride and cholesterol. **D:** Immunoblot analysis of plasma detected with an anti-apoB antibody. **E:** Immunoblot analysis of liver microsomes detected with an anti-apoB antibody. **F:** Immunoblot analysis of liver microsomes detected with antibodies as indicated. Each bar graph value represents the mean  $\pm$  SD. \* $P < 0.02$ .

tion of apoB-48 (Fig. 2E). The MTP inhibitor did not affect the levels of microsomal luminal chaperone proteins (Fig. 2F) or of cytosolic HSPs (Fig. 2F). These findings suggest that the liver adapts to inhibition of apoB secretion and prevents the accumulation of apoB in the ER.


We next examined the hepatic response to MTP inhibition in extremely hyperbetalipoproteinemic *Ldlr*<sup>-/-</sup> mice. Chemical inhibition of MTP did not increase liver weight (Fig. 3A), perhaps because *Ldlr*<sup>-/-</sup> mice already have enlarged livers; however, there were decreases in the plasma levels of cholesterol (85%), triglyceride (65%) (Fig. 3B), apoB-100 (70%), and apoB-48 (80%) (Fig. 3D). As a result, plasma VLDL, IDL, and LDL essentially disappeared, and HDL levels decreased by 65% (Fig. 3B). In the livers of mice, the stores of triglycerides increased 4-fold and cholesterol increased 2-fold (Fig. 3C). Despite the marked decrease in apoB secretion, hepatic microsomes contained almost no apoB-100, and there was no accumulation of apoB-48 (Fig. 3E). Microsomes from *Ldlr*<sup>-/-</sup> mice not treated with the MTP inhibitor contained markedly more apoB-100 than microsomes from untreated wild-type mice (Fig. 3F). Thus, the absence of the LDL receptor caused apoB-100 to accumulate in the ER of mice not treated with MTP. The MTP inhibitor did not affect the content of any microsomal luminal chaperone proteins

(Fig. 3G) or the content of cytosolic HSPs (Fig. 3G). These data show that inhibition of MTP ameliorates severe hypercholesterolemia without causing accumulation of apoB in the ER, hepatic inflammation, or massive fatty liver.

To determine how rapidly apoB degradation is induced in response to MTP inhibition, we assessed the effects of a single dose of the MTP inhibitor. A single dose of 8aR did not alter liver weight (Fig. 4A). It did, however, reduce plasma levels of triglycerides (43%) and cholesterol (22%) (Fig. 4B), apoB-100 (95%), and apoB-48 (88%) (Fig. 4D). Neither apoB isoform accumulated in the microsomal fractions (Fig. 4E). Hepatic levels of markers of the HSP and unfolded protein responses were also unaffected (Fig. 4F). These findings show that the hepatic response to MTP inhibition and impaired apoB secretion is sufficiently rapid to prevent the apoB accumulation in the ER. This rapid response may help to explain the absence of an accumulation of misfolded proteins in the ER and an associated inflammatory response.

## DISCUSSION

This study shows, for the first time, that blocking hepatic apoB secretion in vivo in mice results in a rapid ho-



**Fig. 3.** Effect of 7 days of treatment with an oral MTP inhibitor on the plasma and liver levels of apoB-containing lipoproteins in *Ldlr*<sup>-/-</sup> mice. Female C57BL/6 mice (8 weeks old) were given the MTP inhibitor 8aR (50 mg/day/kg) for 7 days at 0800 h or vehicle only (control). Mice were sacrificed at 1100 h, and plasma and livers were obtained and analyzed. **A:** Body and liver weights. **B:** Plasma triglyceride and cholesterol, and cholesterol in each fraction obtained from FPLC separation of pooled plasma (five mice in each group). **C:** Liver triglyceride and cholesterol. **D:** Immunoblot analysis of plasma detected with an anti-apoB antibody. **E:** Immunoblot analysis of liver microsomes detected with an anti-apoB antibody. **F:** Immunoblot analysis of liver microsomes obtained from wild-type C57BL/6 and *Ldlr*<sup>-/-</sup> mice detected with an anti-apoB antibody. **G:** Immunoblot analysis of liver microsomes detected with antibodies as indicated. Each bar graph value represents the mean  $\pm$  SD. \* $P < 0.02$ .

meostatic degradation pathway that prevents the accumulation of apoB in the ER without inducing heat shock or unfolded protein responses. Blocking MTP function by *Cre*-mediated gene disruption or chemical inhibition also reduced plasma lipid levels markedly without causing massive fatty liver. These findings suggest that MTP could be an effective therapeutic target for hyperlipidemia.

The processes through which apoB is assembled into lipoproteins and secreted by the liver are complex and controlled at many different levels throughout the secretory pathway [reviewed in refs. (16–20)]. Since MTP is localized to the proximal portion of the secretory pathway (i.e., the ER) (42), we have focused these studies on exam-

ining how blocking MTP affects the ER content of apoB and of luminal proteins that participate in the unfolded protein response. Our findings are the first to show that in vivo deletion of MTP function (either by *Cre*-mediated gene disruption or chemical inhibition) blocked hepatic secretion of apoB-100 without causing apoB to accumulate in the ER. These findings are consistent with the notion that while loss of MTP function blocks apoB translocation, apoB does not accumulate in the ER (21, 25, 43–45) because it is cotranslationally degraded (30, 37, 46, 47). Our finding that interruption of MTP function results in the rapid and efficient degradation of secretion-incompetent apoB in vivo explains why apoB does not ac-

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.